

## REMARKS/ARGUMENTS

The Examiner has required that the present invention be restricted to one of the following Groups as required under 35 U.S.C. 121.

- I. Claims 1-10 and 18-25, are drawn to products of the formula (I), (II), (III), (IIIa), or (IV) classified in various subclasses of classes 514, 546 and 548.
- II. Claims 26 and 27, are drawn to methods of use for the products of the formula (I), (II), (III), (IIIa), or (IV) classified in various subclasses of class 514.
- III. Claim 28, is drawn to methods of preparation for the products of the formula (I), (II), (III), (IIIa), or (IV) classified in various subclasses of class 514.

Applicants elect Group I without traverse.


Further, the Examiner requires that where an election of any Groups I-III is made, an election of a single compound is further required. For purposes of examination Applicants select Example 88, on page 38 of the specification as originally filed.

Claims 26-28 have been withdrawn because of the restriction requirement. Applicants reserve their rights to file a divisional(s) application on any material restricted in response to this communication.

In view of the remarks and the amendments, further and favourable consideration of the present application and the allowance of all pending claims are respectfully requested. The Examiner is also invited to contact the undersigned should the Examiner believe that such contact would expedite prosecution of the present application.

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-2614

  
Gregory C. Houghton  
Attorney for Applicants  
Reg. No. 47,666

Date: August 25, 2006